This work is licensed under the Creative Commons Attribution 4.0 International License.
Dogan I, Tastekin D, Karabulut S, Sakar B. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. J Dig Dis 2022; 23: 493–9. doi: 10.1111/1751-2980.13123DoganITastekinDKarabulutSSakarBCapecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumorsJ Dig Dis202223493910.1111/1751-2980.13123Open DOISearch in Google Scholar
Al-Toubah T, Pelle E, Valone T, Haider M, Strosberg JR. Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms. J Natl Compr Canc Netw 2021; 20: 29–36. doi: 10.6004/jnccn.2021.7017Al-ToubahTPelleEValoneTHaiderMStrosbergJREfficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasmsJ Natl Compr Canc Netw202120293610.6004/jnccn.2021.7017Open DOISearch in Google Scholar
Arrivi G, Verrico M, Roberto M, Barchiesi G, Faggiano A, Marchetti P, et al. Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis. Cancer Manag Res 2022; 14: 3507–23. doi: 10.2147/cmar.S372776ArriviGVerricoMRobertoMBarchiesiGFaggianoAMarchettiPCapecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysisCancer Manag Res20221435072310.2147/cmar.S372776Open DOISearch in Google Scholar
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 844–60. doi: 10.1016/j.annonc.2020.03.304PavelMÖbergKFalconiMKrenningEPSundinAPerrenAGastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol2020318446010.1016/j.annonc.2020.03.304Open DOISearch in Google Scholar
Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors With temozolomide and capecitabine. J Clin Oncol 2005; 23: 4216. doi: 10.1200/jco.2005.23.16_suppl.4216FineRLFogelmanDRSchreibmanSMEffective treatment of neuroendocrine tumors With temozolomide and capecitabineJ Clin Oncol200523421610.1200/jco.2005.23.16_suppl.4216Open DOISearch in Google Scholar
Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016; 23: 759–67. doi: 10.1530/erc-16-0147CivesMGhayouriMMorseBBrelsfordMBlackMRizzoAAnalysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumorsEndocr Relat Cancer2016237596710.1530/erc-16-0147Open DOISearch in Google Scholar
Wang W, Zhang Y, Peng Y, Jin KZ, Li YL, Liang Y, et al. A Ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study. Neuroendocrinology 2021; 111: 752–63. doi: 10.1159/000510159WangWZhangYPengYJinKZLiYLLiangYA Ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter studyNeuroendocrinology20211117526310.1159/000510159Open DOISearch in Google Scholar
Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study). Br J Cancer 2019; 121: 537–44. doi: 10.1038/s41416-019-0558-7Solis-HernandezMPFernandez Del ValleACarmona-BayonasAGarcia-CarboneroRCustodioABenaventMEvaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study)Br J Cancer20191215374410.1038/s41416-019-0558-7Open DOISearch in Google Scholar
Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, et al. Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. Clin Mol Hepatol 2014; 20: 218–22. doi: 10.3350/cmh.2014.20.2.218ChoiJIImagawaDKBhosalePBhargavaPTirkesTSeeryTEMagnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenibClin Mol Hepatol2014202182210.3350/cmh.2014.20.2.218Open DOISearch in Google Scholar
Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015; 34: 823–42. doi: 10.1007/s10555-015-9598-5Garcia-CarboneroRGarcia-FigueirasRCarmona-BayonasASevillaITeuleAQuindosMImaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentCancer Metastasis Rev2015348234210.1007/s10555-015-9598-5Open DOISearch in Google Scholar
Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 2014; 120: 711–21. doi: 10.1002/cncr.28493KrajewskiKMNishinoMFranchettiYRamaiyaNHVan den AbbeeleADChoueiriTKIntraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteriaCancer20141207112110.1002/cncr.28493Open DOISearch in Google Scholar
Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 2013; 40: 897–907. doi: 10.1007/s00259-013-2371-5Schmid-TannwaldCSchmid-TannwaldCMMorelliJNNeumannRHaugARJansenNComparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreasEur J Nucl Med Mol Imaging20134089790710.1007/s00259-013-2371-5Open DOISearch in Google Scholar
Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461–75. doi: 10.1007/s00428-002-0609-xPapottiMBongiovanniMVolanteMAllìaELandolfiSHelboeLExpression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysisVirchows Arch20024404617510.1007/s00428-002-0609-xOpen DOISearch in Google Scholar
Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010; 35: 321–8. doi: 10.1097/RLU.0b013e3181d6677cVersariACamelliniLCarlinfanteGFrasoldatiANicoliFGrassiEGa-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective studyClin Nucl Med201035321810.1097/RLU.0b013e3181d6677cOpen DOISearch in Google Scholar
Singh S, Poon R, Wong R, Metser U. 68Ga PET Imaging in patients with neuroendocrine tumors: A systematic review and meta-analysis. Clin Nucl Med 2018; 43: 802–10. doi: 10.1097/rlu.0000000000002276SinghSPoonRWongRMetserU68Ga PET Imaging in patients with neuroendocrine tumors: A systematic review and meta-analysisClin Nucl Med2018438021010.1097/rlu.0000000000002276Open DOISearch in Google Scholar
Koch W, Auernhammer CJ, Geisler J, Spitzweg C, Cyran CC, Ilhan H, et al. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. Mol Imaging 2014; 13: 1–10. doi: 10.2310/7290.2014.00009KochWAuernhammerCJGeislerJSpitzwegCCyranCCIlhanHTreatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomographyMol Imaging20141311010.2310/7290.2014.00009Open DOISearch in Google Scholar
Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010; 51: 1349–56. doi: 10.2967/jnumed.110.075002HaugARAuernhammerCJWanglerBSchmidtGPUebleisCGokeB68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumorsJ Nucl Med20105113495610.2967/jnumed.110.075002Open DOISearch in Google Scholar
Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, et al. (68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE). Cancers 2021; 13. doi: 10.3390/cancers13174321IngenerfMKieslSKarimSBeyerLIlhanHRübenthalerJ(68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE)Cancers20211310.3390/cancers13174321Open DOISearch in Google Scholar
Filippi L, Scopinaro F, Pelle G, Cianni R, Salvatori R, Schillaci O, et al. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2016; 43: 432–40. doi: 10.1007/s00259-015-3178-3FilippiLScopinaroFPelleGCianniRSalvatoriRSchillaciOMolecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumoursEur J Nucl Med Mol Imaging2016434324010.1007/s00259-015-3178-3Open DOISearch in Google Scholar
Peixoto RD, Noonan KL, Pavlovich P, Kennecke HF, Lim HJ. Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs. J Gastrointest Oncol 2014; 5: 247–52. doi: 10.3978/j.issn.2078-6891.2014.019PeixotoRDNoonanKLPavlovichPKenneckeHFLimHJOutcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETsJ Gastrointest Oncol201452475210.3978/j.issn.2078-6891.2014.019Open DOISearch in Google Scholar
Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol 2023; 41: 1359–69. doi: 10.1200/jco.22.01013KunzPLGrahamNTCatalanoPJNimeiriHSFisherGALongacreTARandomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)J Clin Oncol20234113596910.1200/jco.22.01013Open DOISearch in Google Scholar
Owen DH, Alexander AJ, Konda B, Wei L, Hemminger JA, Schmidt CR, et al. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget 2017; 8: 104046–56. doi: 10.18632/oncotarget.22001OwenDHAlexanderAJKondaBWeiLHemmingerJASchmidtCRCombination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for responseOncotarget201781040465610.18632/oncotarget.22001Open DOISearch in Google Scholar
Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interv Imaging 2014; 95: 289–300. doi: 10.1016/j.diii.2013.07.006ÖksüzMÖWinterLPfannenbergCReischlGMüssigKBaresRPeptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?Diagn Interv Imaging20149528930010.1016/j.diii.2013.07.006Open DOISearch in Google Scholar
Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol 2015; 17: 313–8. doi: 10.1007/s11307-014-0795-3KratochwilCStefanovaMMavriopoulouEHolland-LetzTDimitrakopoulou-StraussAAfshar-OromiehASUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumorsMol Imaging Biol201517313810.1007/s11307-014-0795-3Open DOISearch in Google Scholar
Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. (68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol 2019; 141: 108–15. doi: 10.1016/j.radonc.2019.09.003SharmaRWangWMYusufSEvansJRamaswamiRWernigF(68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumoursRadiother Oncol20191411081510.1016/j.radonc.2019.09.003Open DOISearch in Google Scholar
Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, et al. Early changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer. Cancers 2020; 12. doi: 10.3390/cancers12113314SiricoMBernocchiOSobhaniNGiudiciFCoronaSPVernieriCEarly changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancerCancers20201210.3390/cancers12113314Open DOISearch in Google Scholar
Michl M, Lehner S, Paprottka PM, Ilhan H, Bartenstein P, Heinemann V, et al. Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer. J Nucl Med 2016; 57: 355–60. doi: 10.2967/jnumed.115.165613MichlMLehnerSPaprottkaPMIlhanHBartensteinPHeinemannVUse of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancerJ Nucl Med2016573556010.2967/jnumed.115.165613Open DOISearch in Google Scholar
Ingenerf M, Kiesl S, Winkelmann M, Auernhammer CJ, Rübenthaler J, Grawe F, et al. Treatment assessment of pNET and NELM after everolimus by quantitative MRI parameters. Biomedicines 2022; 10. doi: 10.3390/biomedicines10102618IngenerfMKieslSWinkelmannMAuernhammerCJRübenthalerJGraweFTreatment assessment of pNET and NELM after everolimus by quantitative MRI parametersBiomedicines20221010.3390/biomedicines10102618Open DOISearch in Google Scholar
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753–9. doi: 10.1200/jco.2006.07.3049ChoiHCharnsangavejCFariaSCMacapinlacHABurgessMAPatelSRCorrelation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteriaJ Clin Oncol2007251753910.1200/jco.2006.07.3049Open DOISearch in Google Scholar
Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinology 2018; 14: 656–69. doi: 10.1038/s41574-018-0082-5HoflandJZandeeWTde HerderWWRole of biomarker tests for diagnosis of neuroendocrine tumoursNat Rev Endocrinology2018146566910.1038/s41574-018-0082-5Open DOISearch in Google Scholar
Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, et al. Biomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management – an updated review. Frontiers Oncol 2020; 10: 831. doi: 10.3389/fonc.2020.00831BocchiniMNicoliniFSeveriSBongiovanniAIbrahimTSimonettiGBiomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management – an updated reviewFrontiers Oncol20201083110.3389/fonc.2020.00831Open DOISearch in Google Scholar
Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 111–34. doi: doi.org/10.1016/j.ecl.2010.12.001LawrenceBGustafssonBIKiddMPavelMSvejdaBModlinIMThe clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumorsEndocrinol Metab Clin North Am20114011134doi: doi.org/10.1016/j.ecl.2010.12.001Search in Google Scholar
Strosberg JR, Cives M, Brelsford M, Black M, Meeker A, Ghayouri M. Identification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. J Clin Oncolog 2015; 33: 4099. doi: 10.1200/jco.2015.33.15_suppl.4099StrosbergJRCivesMBrelsfordMBlackMMeekerAGhayouriMIdentification of response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumorsJ Clin Oncolog201533409910.1200/jco.2015.33.15_suppl.4099Open DOISearch in Google Scholar
Spada F, Antonuzzo L, Marconcini R, Gelsomino F, Fumagalli C, Messerini L, et al. Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multi-center retrospective analysis. J Clin Oncol 2015; 33: e15174-e. doi: 10.1200/jco.2015.33.15_suppl.e15174SpadaFAntonuzzoLMarconciniRGelsominoFFumagalliCMesseriniLChemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multi-center retrospective analysisJ Clin Oncol201533e15174-e10.1200/jco.2015.33.15_suppl.e15174Open DOISearch in Google Scholar
O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016; 280: 576–84. doi: 10.1148/radiol.2016142043OJHLodgeMAWahlRLPractical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0Radiology20162805768410.1148/radiol.2016142043Open DOISearch in Google Scholar
Opalińska M, Morawiec-Sławek K, Kania-Kuc A, Al Maraih I, Sowa-Staszczak A, Hubalewska-Dydejczyk A. Potential value of pre- and post-therapy [68Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol 2022; 13: 929391. doi: 10.3389/fendo.2022.929391OpalińskaMMorawiec-SławekKKania-KucAAl MaraihISowa-StaszczakAHubalewska-DydejczykAPotential value of pre- and post-therapy [68Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumorsFront Endocrinol20221392939110.3389/fendo.2022.929391Open DOISearch in Google Scholar
Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE. J Nuclear Med 2020; 61: 217–21. doi: 10.2967/jnumed.119.228072IlanEVelikyanISandströmMSundinALubberinkMTumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATEJ Nuclear Med2020612172110.2967/jnumed.119.228072Open DOISearch in Google Scholar